Advance Search
MA Kaiyue, ZHANG Shu, HUANG Shixin, LI Xiaobo. Effect of Siwu Wuzi Decoction on vascular endothelial growth factor, transforming growth factor-β1 and inflammatory factor levels in patients with wet age-related macular degeneration[J]. Journal of Clinical Medicine in Practice, 2025, 29(4): 6-10. DOI: 10.7619/jcmp.20244475
Citation: MA Kaiyue, ZHANG Shu, HUANG Shixin, LI Xiaobo. Effect of Siwu Wuzi Decoction on vascular endothelial growth factor, transforming growth factor-β1 and inflammatory factor levels in patients with wet age-related macular degeneration[J]. Journal of Clinical Medicine in Practice, 2025, 29(4): 6-10. DOI: 10.7619/jcmp.20244475
shu

Effect of Siwu Wuzi Decoction on vascular endothelial growth factor, transforming growth factor-β1 and inflammatory factor levels in patients with wet age-related macular degeneration

  • 1.

    School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 102488

  • 2.

    Medical Affair Department, Beijing Emergency Medical Center, Beijing, 100031

  • 3.

    Medical Affair Department, Eye Hospital of China Academy of Chinese Medical Sciences, Beijing, 100040

  • 4.

    Hospital Infection Department, Eye Hospital of China Academy of Chinese Medical Sciences, Beijing, 100040

More Information
  • Received Date: September 24, 2024
  • Revised Date: November 05, 2024
    Graphical Abstract
    • Abstract
  • Objective 

    To investigate the effect of Siwu Wuzi Decoction in the treatment of wet age-related macular degeneration (wAMD) on the levels of vascular endothelial growth factor (VEGF), transforming growth factor-β1 (TGF-β1), and inflammatory factors in patients.

    Methods 

    A total of 216 patients with wAMD were randomly divided into western medicine group (n=108) and integrated Chinese and western medicine group (n=108). The western medicine group received conbercept plus photodynamic therapy (PDT), while the integrated Chinese and western medicine group received conbercept, PDT, and Siwu Wuzi Decoction. Both groups were treated for 3 months. The traditional Chinese medicine syndrome scores, best-corrected visual acuity (BCVA), intraocular pressure, VEGF, TGF-β1, inflammatory factor levels[interleukin (IL)-6, IL-13], quality of life [Chinese Low Vision Quality of Life Scale (CLVQOL)], and clinical efficacy were observed in both groups.

    Results 

    After treatment, the traditional Chinese medicine syndrome scores decreased in both groups, with the scores in the integrated Chinese and western medicine group being lower than those in the western medicine group (P < 0.05). After treatment, BCVA decreased in both groups, with the BCVA in the integrated Chinese and western medicine group being lower than that in the western medicine group (P < 0.05). After treatment, intraocular pressure increased in both groups, but the intraocular pressure in the integrated Chinese and western medicine group was lower than that in the western medicine group (P < 0.05). After treatment, VEGF and TGF-β1 levels decreased in both groups, with the levels in the integrated Chinese and western medicine group being lower than those in the western medicine group (P < 0.05). After treatment, IL-6 and IL-13 levels decreased in both groups, with the levels in the integrated Chinese and western medicine group being lower than those in the western medicine group (P < 0.05). After treatment, CLVQOL scores increased in both groups, with the scores in the integrated Chinese and western medicine group being higher than those in the western medicine group (P < 0.05). The total effective rate of treatment in the integrated Chinese and western medicine group was 97.22%, which was higher than 85.19% in the western

    Conclusions 

    Siwu Wuzi Decoction has a good therapeutic effect on wAMD, which can alleviate symptoms, restore vision, reduce intraocular pressure, regulate VEGF, TGF-β1, and inflammatory factor levels, and improve quality of life.

    • FullText(HTML)
    • References (22)
  • [1]
    MATSUMOTO H, HOSHINO J, NAKAMURA K, et al. Short-term outcomes of intravitreal faricimab for treatment-naÏve neovascular age-related macular degeneration[J]. Graefes Arch Clin Exp Ophthalmol, 2023, 261(10): 2945-2952. doi: 10.1007/s00417-023-06116-y
    [2]
    MORI R, HONDA S, GOMI F, et al. Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial[J]. Jpn J Ophthalmol, 2023, 67(3): 301-310. doi: 10.1007/s10384-023-00985-w
    [3]
    MARUYAMA-INOUE M, YANAGI Y, INOUE T, et al. Comparison of functional and morphologic changes between brolucizumab and faricimab in neovascular age-related macular degeneration[J]. Graefes Arch Clin Exp Ophthalmol, 2024, 262(2): 589-599. doi: 10.1007/s00417-023-06241-8issn.1006-6535.2014.02.010xml&restype=unixref&xml=|Connection Science||18|2|173|2006|||
    [4]
    GAO L Q, SONG Y P, SUN X D, et al. Safety and efficacy of intravitreal injection of conbercept for the treatment of patients with choroidal neovascularization secondary to pathological myopia: Results from the SHINY study[J]. Acta Ophthalmol, 2024, 102(4): e577-e586.
    [5]
    WULF H C, HEERFORDT I M. Counteracting side-effects of photodynamic therapy for actinic keratoses[J]. Anticancer Res, 2022, 42(10): 5017-5020. doi: 10.21873/anticanres.16009
    [6]
    葛蓁, 郭晓玲, 李成芳, 等. 四物五子汤联合玻璃体腔注射康柏西普治疗湿性ARMD疗效及对血清细胞因子的影响[J]. 国际眼科杂志, 2022, 22(6): 931-935.
    [7]
    范真, 郭晓玲, 姜文静, 等. 四物五子汤治疗视网膜中央静脉阻塞继发黄斑水肿的临床疗效研究[J]. 中国医院用药评价与分析, 2023, 23(3): 300-303, 307.
    [8]
    中华医学会眼科学分会眼底病学组中国老年性黄斑变性临. 中国老年性黄斑变性临床诊断治疗路径[J]. 中华眼底病杂志, 2013, 29(4): 343-355.
    [9]
    国家中医药管理局. 中医病证诊断疗效标准: ZY/T001.1-001. 9-94[M]. 南京: 南京大学出版社, 1994: 87-89.
    [10]
    郑筱萸. 中药新药临床研究指导原则: 试行[M]. 北京: 中国医药科技出版社, 2002: 22-26.
    [11]
    庄苹, 杨锦, 郑蛟, 等. 化裁四物五子汤治疗年龄相关性黄斑变性疗效及对中医证候积分、视力、眼底情况的影响[J]. 四川中医, 2021, 39(8): 173-176.
    [12]
    WOO S J, BRADVICA M, VAJAS A, et al. Efficacy and safety of the aflibercept biosimilar SB15 in neovascular age-related macular degeneration: a phase 3 randomized clinical trial[J]. JAMA Ophthalmol, 2023, 141(7): 668-676. doi: 10.1001/jamaophthalmol.2023.2260
    [13]
    WEI W, ANANTHARANJIT R, PATEL R P, et al. Detection of macular atrophy in age-related macular degeneration aided by artificial intelligence[J]. Expert Rev Mol Diagn, 2023, 23(6): 485-494. doi: 10.1080/14737159.2023.2208751
    [14]
    HAN X T, CHEN Y X, GORDON I, et al. A systematic review of clinical practice guidelines for age-related macular degeneration[J]. Ophthalmic Epidemiol, 2023, 30(3): 213-220. doi: 10.1080/09286586.2022.2059812
    [15]
    WEINSTEIN O, COHEN A D, LEVY J, et al. Anxiety in patients with neovascular age-related macular degeneration[J]. Ophthalmic Epidemiol, 2023, 30(3): 286-292. doi: 10.1080/09286586.2022.2090007
    [16]
    WANG Q, CAI H, XU D H, et al. Pars Plana vitrectomy assisted by intravitreal injection of conbercept enhances the therapeutic effect and quality of life in patients with severe proliferative diabetic retinopathy[J]. Am J Transl Res, 2022, 14(2): 1324-1331.
    [17]
    LI H S, NIU Y L, RONG A, et al. Effect of adjunctive intravitreal conbercept injection at the end of 25G vitrectomy on severe proliferative diabetic retinopathy: 6-month outcomes of a randomised controlled trial[J]. Ophthalmol Ther, 2023, 12(2): 1173-1180. doi: 10.1007/s40123-023-00664-6
    [18]
    KESSEL D. Photodynamic therapy: critical PDT theory[J]. Photochem Photobiol, 2023, 99(2): 199-203. doi: 10.1111/php.13616
    [19]
    高健, 李萌, 王彦彦, 等. 益肾养肝明目方联合抗VEGF药物治疗湿性年龄相关性黄斑变性[J]. 国际眼科杂志, 2023, 23(8): 1362-1366.
    [20]
    李锦媛, 苏风军. 基于"一气周流" 理论论治湿性年龄相关性黄斑变性探析[J]. 中国中医眼科杂志, 2023, 33(8): 762-765.
    [21]
    史随随, 周剑, 罗越毅, 等. 四桑明目方联合抗新生血管药物治疗湿性年龄相关性黄斑变性的临床疗效及经济学价值[J]. 现代中西医结合杂志, 2023, 32(24): 3394-3400.
    [22]
    李晓宇, 梁丽娜, 田少磊, 等. 凉血化瘀法治疗湿性年龄相关性黄斑变性的Meta分析及用药规律总结[J]. 中国中医眼科杂志, 2022, 32(5): 408-415.
    • Related Articles

  • Related Articles

    [1]MAO Tingting, JIANG Qiong, WANG Yan, MING Xia, LOU Yinghua. Correlations of serum transforming growth factor-β1 and insulin-like growth factor-1 with pathological features and postoperative recurrence in patients with adenomyosis[J]. Journal of Clinical Medicine in Practice, 2025, 29(4): 103-107. DOI: 10.7619/jcmp.20243572
    [2]HOU Guoqing, YUE Hailong, CHANG Qian, MA Juntao. Effect of dexmedetomidine on epidural fibrosis afterspinal surgery in rats via the transforming growth factor-β1 pathway[J]. Journal of Clinical Medicine in Practice, 2025, 29(1): 77-82. DOI: 10.7619/jcmp.20243181
    [3]RAN Qian, FAN Chonggui, MA Weifeng, LI Shuaiqi. Associations of serum transforming growth factor-β1 and klotho expression levels with disease severity and cognitive function in patients with epilepsy[J]. Journal of Clinical Medicine in Practice, 2025, 29(1): 56-60. DOI: 10.7619/jcmp.20241976
    [4]ZHANG Jing, MAO Ying. Value of combined assessment of serum transforming growth factor-β1, interleukin-6, toll-like receptor-4, and nuclear factor-κb in evaluating the severity of radiation pneumonitis in non-small cell lung cancer[J]. Journal of Clinical Medicine in Practice, 2024, 28(14): 12-17. DOI: 10.7619/jcmp.20234065
    [5]MENG Lijun, GUO Xiaohe, DONG Daiyuan, YANG Yan, XUE Yaofeng, ZHOU Baolin, QIN Yongmei. Effect of thalidomide combined with infliximab in treatment of refractory inflammatory bowel disease and its effects on insulin-like growth factor-1 and transforming growth factor-β1[J]. Journal of Clinical Medicine in Practice, 2024, 28(1): 68-72, 77. DOI: 10.7619/jcmp.20230274
    [6]ZHUANG Lixia, ZHANG Jie, CHEN Peixin. Application value of serum transforming growth factor-β1 and alkaline phosphatase in diagnosing severe neonatal necrotizing enterocolitis[J]. Journal of Clinical Medicine in Practice, 2023, 27(19): 67-70. DOI: 10.7619/jcmp.20232084
    [7]SHEN Yuguo, CHEN Qian. Influence of jinshi nephritis pills on gamma-glutamyl transpeptidase, homocysteine, transforming growth factor-β1 and cystatin C levels in diabetic nephropathy patients[J]. Journal of Clinical Medicine in Practice, 2017, (15): 37-40. DOI: 10.7619/jcmp.201715010
    [8]LI Hehua, LI Tong, SONG Zhixiu. Influence of transforming growth factor-β1 on expression of connective tissue growth factor in astrocytes in neonatal rat[J]. Journal of Clinical Medicine in Practice, 2015, (9): 5-8. DOI: 10.7619/jcmp.201509002
    [9]LIU Yulei, YANG Dongsheng. Expression levels and significance of EGF,TGF-β1 of skin mesenchymal stem cells in patients with psoriasis[J]. Journal of Clinical Medicine in Practice, 2014, (16): 78-80,84. DOI: 10.7619/jcmp.201416022
    [10]ZHU Chun, HUANG Haidong, WANG Lirui, GUO Zhiyong. Influence of heme oxygenase-1 on expressions of transforming growth factor-β1 and fibronectin in peritoneal mesothelial cells of rats induced by high glucose[J]. Journal of Clinical Medicine in Practice, 2014, (1): 1-4. DOI: 10.7619/jcmp.201401001

  • Cited by

    Periodical cited type(59)

    1. 胡艳，万德仁，黄丽红. 电针联合穴位敷贴在精神分裂症残留阴性症状患者中的应用. 光明中医. 2024(03): 553-556 .
    2. 谢滨浩，朱婕，梁睿. 松弛疗法对精神分裂症住院患者的疗效分析. 心理月刊. 2024(19): 120-122 .
    3. 徐孝荣，张娇娇. 齐拉西酮与奥氮平治疗精神分裂症的疗效及其对患者糖、脂代谢影响的比较. 现代医学与健康研究电子杂志. 2023(21): 7-9 .
    4. 郭辉. 齐拉西酮和奥氮平治疗老年精神分裂症患者的效果及对机体糖脂代谢的影响. 当代医学. 2022(03): 53-55 .
    5. 孙磊，罗国帅，陈清刚. 布南色林与利培酮对首发精神分裂症患者认知功能、泌乳素和血脂的影响研究. 中国慢性病预防与控制. 2022(03): 214-217 .
    6. 冯健超，杨国瑛. 利培酮联合氯氮平治疗难治性精神分裂症的临床疗效. 临床合理用药杂志. 2022(07): 11-13 .
    7. 裴建琴，张艳，陆江波，张洁，姚梦洁，代金枝，钱维. 团体感觉运动训练对老年精神分裂症患者认知功能、阴性症状的干预效果研究. 军事护理. 2022(09): 13-16 .
    8. 白瑜，王晓东. 无抽搐电休克辅助齐拉西酮对精神分裂症患者多导睡眠图参数及血清SHBG、DHEA-S、GAP-43水平的影响. 临床医学研究与实践. 2022(27): 42-45+53 .
    9. 王政，邵宝富，王超. 奥氮平治疗精神分裂症患者DTI研究. 医学影像学杂志. 2022(10): 1658-1661 .
    10. 王佳琪，佘继林. 捏脊配合杵针对多发性抽动症患儿症状积分及血清兴奋性氨基酸水平的影响观察. 四川中医. 2022(11): 217-220 .
    11. 李雪冰. 齐拉西酮联合奥氮平对老年精神分裂症患者血糖及TC、TG、LDL-C水平的影响. 现代医学与健康研究电子杂志. 2021(02): 3-5 .
    12. 何磊，韩香平，张彦旭，刘莉，马晓亮. 舍曲林联合阿立哌唑治疗精神分裂症后抑郁的临床效果. 河南医学研究. 2021(04): 717-719 .
    13. 曹保瑞，陈家民，马庆. 齐拉西酮联合奥氮平治疗难治性精神分裂症的效果及安全性. 中国当代医药. 2021(10): 113-116 .
    14. 苏玉晨. 补阳还五汤联合奥氮平对精神分裂症症状及NRG1、IL-2水平影响. 中华中医药学刊. 2021(06): 160-162 .
    15. 孟肖婷. 文拉法辛与艾司西酞普兰对抑郁症的控制效果和安全性对比. 中国卫生工程学. 2021(03): 493-495 .
    16. 尚旭立. 齐拉西酮对首发青少年精神分裂症患者认知功能及脑灰质结构的影响. 医药论坛杂志. 2021(14): 104-107 .
    17. 周显华，陈娟红，曾祥林. 奥氮平联合阿立哌唑治疗精神分裂症伴攻击行为的临床观察. 江西医药. 2021(09): 1488-1490 .
    18. 李雪冰. 阿立哌唑与齐拉西酮治疗首发精神分裂症的临床疗效与安全性对比研究. 中国药物与临床. 2021(21): 3596-3598 .
    19. 冯新梅. 奥氮平治疗精神分裂症对患者症状、安全性评分及相关血清因子的影响. 临床荟萃. 2021(12): 1114-1117 .
    20. 刘冠军，张进周. 喹硫平联合认知行为疗法治疗精神分裂症对照研究. 临床心身疾病杂志. 2021(04): 24-26+38 .
    21. 马立强. 文拉法辛联合小剂量氯氮平对难治性精神分裂症患者的疗效及认知及社会功能影响. 当代医学. 2020(07): 129-130 .
    22. 魏学萍. 精神分裂症急性激越症状的急诊药物治疗方法分析. 中国处方药. 2020(02): 89-90 .
    23. 燕银枝，孙洪波. 精神分裂症采用齐拉西酮联合疏肝解郁胶囊治疗的观察. 中国医药科学. 2020(07): 72-74 .
    24. 王小军，张群. 奥氮平与氯丙嗪对慢性精神分裂症患者近期疗效及认知功能的对比分析. 中国药物与临床. 2020(07): 1110-1112 .
    25. 廉燕. 齐拉西酮联合奥氮平对女性首发精神分裂症患者激越及睡眠质量的影响评价. 世界睡眠医学杂志. 2020(05): 911-912 .
    26. 陈琳. 利培酮联合阿立哌唑治疗对精神分裂症患者的有效性及对认知功能的影响. 中国健康心理学杂志. 2020(09): 1289-1292 .
    27. 成加林，牛军涛，何杰，陈财德，周碧海，许晴丽. 齐拉西酮联合改良电休克治疗首发精神分裂症患者的疗效及对血清p-mTOR和IL-18水平的影响. 中国现代医学杂志. 2020(17): 72-76 .
    28. 杜菊梅，阮俊，石晶，黄杨梅，杨寅，朱大凤. 麦芽对药源性血清泌乳素升高及代谢综合征疗效的临床研究. 中外医学研究. 2020(24): 137-139 .
    29. 王雅辞，闫冰雪，关馨瑶. 时间护理对精神分裂症患者危险行为及精神症状的影响. 中华现代护理杂志. 2020(22): 3037-3040 .
    30. 陈慧，郭晓静. 奥氮平联合喹硫平治疗精神分裂症的Meta分析. 中国卫生标准管理. 2020(22): 104-108 .
    31. 陈旋，李宁，高海燕. 帕利哌酮与氨磺必利对首发精神分裂症的疗效及对记忆、认知功能及心律的影响. 神经损伤与功能重建. 2020(12): 759-760 .
    32. 曹书改. 精神分裂症患者盐酸齐拉西酮胶囊治疗期间护理措施及效果. 山西医药杂志. 2020(24): 3533-3535 .
    33. 张德源，谭家蓉，向燕卿. 帕罗西汀联合心理治疗对女性围绝经期情绪障碍、睡眠质量及血清性激素水平的影响. 解放军医药杂志. 2019(01): 74-78 .
    34. 柴建军. 精神分裂症的临床诊治与疗效. 世界最新医学信息文摘. 2019(07): 85-86 .
    35. 丁慧琴，娄渊敏，李海根. 延伸性护理对精神分裂症患者危险行为、精神症状及自我管理的影响. 现代医药卫生. 2019(05): 760-762 .
    36. 张飞龙. 奥氮平与齐拉西酮联合改良型电休克治疗首发精神分裂症应用对比研究. 淮海医药. 2019(03): 297-299 .
    37. 杜菊梅，石晶，徐璐，黄杨梅，常沛沛，徐止浩. 运动疗法配合心理干预对康复期精神分裂症患者病耻感、社会功能及生活质量的影响. 中国健康心理学杂志. 2019(07): 991-996 .
    38. 宋籽良，宋清海，郑昌江. 奥氮平联合焦点解决式健康指导对精神分裂症患者病情及社会认知的影响. 广东医学. 2019(11): 1608-1612 .
    39. 肖建新，胡民，王金钱. 导痰汤加减联合利培酮治疗精神分裂症的临床疗效观察. 北方药学. 2019(07): 22-23 .
    40. 李春娟. 奥氮平联合丁螺环酮治疗精神分裂症阴性症状的疗效及安全性. 中国处方药. 2019(07): 94-95 .
    41. 付飞，陈汉波. 奥氮平联合齐拉西酮对老年重度精神分裂症患者血清学指标和认知功能的影响探讨. 中国医学创新. 2019(24): 32-35 .
    42. 张恒. 奥氮平联合利培酮对改善老年痴呆患者精神行为症状的效果. 临床医学研究与实践. 2019(26): 45-47 .
    43. 焦秀娟，徐东. 帕利哌酮联合经颅磁刺激治疗难治性精神分裂症效果观察. 医药论坛杂志. 2019(09): 22-24 .
    44. 费沛. 奥氮平与氟哌啶醇治疗精神分裂症的效果比较及对血清炎症因子的影响. 实用医药杂志. 2019(11): 997-1000 .
    45. 高章代，戚莉君，薛林霞，吴彬，刘强. 口服盐酸曲唑酮辅助治疗脑卒中后抑郁的疗效研究. 检验医学与临床. 2019(23): 3525-3528 .
    46. 张航雷. 高频rTMS联合氨磺必利治疗精神分裂症阴性症状患者临床研究. 医药论坛杂志. 2019(11): 133-136 .
    47. 姚永新，王年美，邢晓华. 小儿多发性抽动症临床特征及发病因素调查. 中国妇幼保健. 2019(23): 5511-5513 .
    48. 刘丹，李健，陈薇，程亮，刘树利，户文娟，刘文芳. 养血清脑颗粒联合米氮平治疗脑卒中后抑郁伴失眠的临床观察. 湖南中医药大学学报. 2018(05): 582-585 .
    49. 陈登霞，潘竹松. 齐拉西酮与氯丙嗪治疗精神分裂症的疗效比较研究及其对患者心电图的影响. 临床合理用药杂志. 2018(12): 5-6 .
    50. 常凤坤，王会娟. 齐拉西酮针剂序贯口服胶囊治疗精神分裂症激越症的效果及安全性评价. 临床医学工程. 2018(06): 777-778 .
    51. 陈文婷，何海荣. 齐拉西酮和利培酮治疗精神分裂症的临床疗效及安全性. 药品评价. 2018(06): 61-64 .
    52. 何晓燕. 奥氮平对精神分裂症患者肝功能、血糖、血脂水平的影响. 中国民康医学. 2018(15): 69-70 .
    53. 续慧蕾，刘勇，蒋茜，杜秋蓉. 用齐拉西酮与奥氮平对首发精神分裂症患者进行治疗的效果探讨. 当代医药论丛. 2018(19): 153-154 .
    54. 陈明森，周春闽. 齐拉西酮与奥氮平治疗老年精神分裂症疗效及对血糖、血脂水平的影响分析. 糖尿病新世界. 2018(20): 56-58 .
    55. 庄艳云，吕霞，陈言钊，周克英. 氟哌啶醇治疗伴脑电图异常小儿多发性抽动症疗效观察. 国际神经病学神经外科学杂志. 2018(06): 556-559 .
    56. 洪二郎，常凤坤. 齐拉西酮胶囊联合奥氮平治疗高龄精神分裂症患者疗效及对精神症状、糖脂代谢和BMI的影响. 中国医药科学. 2018(24): 38-40+68 .
    57. 曹宏波，崔林梅，黄自州，牟洋. 齐拉西酮联合无抽搐电休克治疗精神分裂症的血清指标及电生理特征评价. 海南医学院学报. 2017(06): 847-850+854 .
    58. 华浩水，陆源昕，邵剑锋. 阿立哌唑联合齐拉西酮治疗精神分裂症患者的临床效果分析. 现代实用医学. 2017(05): 669-670 .
    59. 唐芸. 盐酸美金刚片联合多奈哌齐治疗老年痴呆的临床疗效观察. 中国现代医生. 2017(35): 111-113 .

    Other cited types(9)

Catalog

    Get Citation
    PDF
    XML
    Article views (64) PDF downloads (13) Cited by(68)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return